Optimization of the preparation process for human serum albumin (HSA) nanoparticles

被引:632
作者
Langer, K
Balthasar, S
Vogel, V
Dinauer, N
von Briesen, H
Schubert, D
机构
[1] Univ Frankfurt, Inst Pharmazeut Technol, D-60439 Frankfurt, Germany
[2] Univ Frankfurt, Inst Biophys, D-60590 Frankfurt, Germany
[3] Inst Biomed Res, D-60552 Frankfurt, Germany
关键词
nanoparticles; human serum albumin (HSA); particle size distribution; cellular uptake;
D O I
10.1016/S0378-5173(03)00134-0
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nanoparticles prepared by desolvation and subsequent crosslinking of human serum albumin (HSA) represent promising carriers for drug delivery. Particle size is a crucial parameter, in particular for the in vivo behaviour of nanoparticles after intravenous injection. The objective of the present study is the development of a desolvation procedure for the preparation of HSA-based nanoparticles under the aspect of a controllable particle size between 100 and 300 nm in combination with a narrow size distribution. A pump-controlled preparation method was established which enabled particle preparation under defined conditions. Several factors of the preparation process, such as the rate of addition of the desolvating agent, the pH value and the ionic composition of the HSA solution, the protein concentration, and the conditions of particle purification were evaluated. The pH value of the HSA solution prior to the desolvation procedure was identified as the major factor determining particle size. Varying this parameter, (mean) particle diameters could be adjusted between 150 and 280 nm, higher pH values leading to smaller nanoparticles. Washing the particles by differential centrifugation led to significantly narrower size distributions. The reproducibility of the particle size and particle size distribution under the proposed preparation conditions was demonstrated by sedimentation velocity analysis in the analytical ultracentrifuge and the cellular uptake of those nanoparticles was studied by confocal microscope imaging and FACS analysis. The stability of the resulting nanoparticles was evaluated by pH and buffer titration experiments. Only pH values distinctly outside the isoelectric pH range of HSA and low salt concentrations were able to prevent nanoparticle agglomeration. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:169 / 180
页数:12
相关论文
共 19 条
  • [1] CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153
  • [2] ANALYSIS OF ALBUMIN MICROSPHERE PREPARATION
    GALLO, JM
    HUNG, CT
    PERRIER, DG
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1984, 22 (01) : 63 - 74
  • [3] ENHANCED HEPATIC-UPTAKE OF LIPOSOMES THROUGH COMPLEMENT ACTIVATION DEPENDING ON THE SIZE OF LIPOSOMES
    HARASHIMA, H
    SAKATA, K
    FUNATO, K
    KIWADA, H
    [J]. PHARMACEUTICAL RESEARCH, 1994, 11 (03) : 402 - 406
  • [4] RAPID CONFIRMATION AND REVISION OF THE PRIMARY STRUCTURE OF BOVINE SERUM-ALBUMIN BY ESIMS AND FRIT-FAB LC MS
    HIRAYAMA, K
    AKASHI, S
    FURUYA, M
    FUKUHARA, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1990, 173 (02) : 639 - 646
  • [5] Preparation of avidin-labeled protein nanoparticles as carriers for biotinylated peptide nucleic acid
    Langer, K
    Coester, C
    Weber, C
    von Briesen, H
    Kreuter, J
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2000, 49 (03) : 303 - 307
  • [6] Preparation of Sub-100 nm Human Serum Albumin Nanospheres Using a pH-Coacervation Method
    Lin, W.
    Coombes, A. G. A.
    Davies, M. C.
    Davis, S. S.
    Illum, L.
    [J]. JOURNAL OF DRUG TARGETING, 1993, 1 (03) : 237 - 243
  • [7] MARTY JJ, 1978, PHARM ACTA HELV, V53, P17
  • [8] Moghimi SM, 2001, PHARMACOL REV, V53, P283
  • [9] Albumin nanospheres as carriers for passive drug targeting: An optimized manufacturing technique
    Muller, BG
    Leuenberger, H
    Kissel, T
    [J]. PHARMACEUTICAL RESEARCH, 1996, 13 (01) : 32 - 37
  • [10] On the mechanism of hepatic transendothelial passage of large liposomes
    Romero, EL
    Morilla, MJ
    Regts, J
    Koning, GA
    Scherphof, GL
    [J]. FEBS LETTERS, 1999, 448 (01) : 193 - 196